Advertisement

Topics

EMA's COMP issues positive opinion on orphan drug status for Santhera's POL6014 to treat cystic fibrosis

05:13 EDT 16 Oct 2018 | PharmaBiz

Santhera Pharmaceuticals has announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on orphan drug designation for POL6014

Original Article: EMA's COMP issues positive opinion on orphan drug status for Santhera's POL6014 to treat cystic fibrosis

NEXT ARTICLE

More From BioPortfolio on "EMA's COMP issues positive opinion on orphan drug status for Santhera's POL6014 to treat cystic fibrosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...